Squamous cell carcinoma (SCC) is the second-most common form of non-melanoma skin cancer (NMSC).
Objective
To provide guidance to Canadian health care practitioners regarding management of SCCs.
Methods
Literature searches and development of graded recommendations were carried out as discussed in the accompanying introduction (chapter 1 of the NMSC guidelines).
Results
SCCs are sometimes confined to the epidermis, but they can also invade nearby tissues and, in some cases, metastasize to neighbouring lymph nodes or other organs. This chapter discusses the natural history, staging, prognosis, and management of SCC—a tumour type that is less common but typically more aggressive than BCC. For this reason, margin control is strongly preferred in treating SCCs.
Conclusions
Although approaches such as cryosurgery and radiation therapy may be considered for some patients, surgical excision—sometimes coupled with radiation—remains the cornerstone of SCC management. Patients with high-risk SCC may also be considered for referral to an appropriate multidisciplinary clinic.
DemersAA, NugentZ, MihalcioiuC, WisemanMC, KliewerEV.Trends of nonmelanoma skin cancer from 1960 through 2000 in a Canadian population.J Am Acad Dermatol.2005; 53(2): 320–328.
2.
GoldmanGD.Squamous cell cancer: a practical approach.Semin Cutan Med Surg.1998; 17(2): 80–95.
3.
RoweDE, CarrollRJ, DayCLJr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip: implications for treatment modality selection.J Am Acad Dermatol.1992; 26(6): 976–990.
4.
LeiterU, GarbeC.Epidemiology of melanoma and nonmelanoma skin cancer: the role of sunlight.Adv Exp Med Biol.2008; 624: 89–103.
RossoS, ZanettiR, MartinezC.The multicentre south European study “Helios.” II: Different sun exposure patterns in the aetiology of basal cell and squamous cell carcinomas of the skin.Br J Cancer.1996; 73(11): 1447–1454.
8.
StulbergDL, CrandellB, FawcettRS.Diagnosis and treatment of basal cell and squamous cell carcinomas.Am Fam Physician.2004; 70(8): 1481–1488.
9.
PoulinY, LyndeCW, BarberK.Non-melanoma skin cancer in Canada chapter 3: management of actinic keratoses.J Cutan Med Surg.2015; 19: 227–238.
10.
FeldmanSR, FleischerABJr. Progression of actinic keratosis to squamous cell carcinoma revisited: clinical and treatment implications.Cutis.2011; 87(4): 201–207.
MartinezJ-C, OtleyCC, StaskoT; Transplant-Skin Cancer Collaborative. Defining the clinical course of metastatic skin cancer in organ transplant recipients.Arch Dermatol.2003; 139: 301–306.
13.
MotleyR, KerseyP, LawrenceC; British Association of Dermatologists, British Association of Plastic Surgeons. Multiprofessional guidelines for the management of the patient with primary cutaneous squamous cell carcinoma.Br J Plast Surg.2003; 56(2): 85–91.
14.
MillerSJ.The National Comprehensive Cancer Network (NCCN) guidelines of care for nonmelanoma skin cancers.Dermatol Surg.2000; 26(3): 289–292.
15.
RudolphR, ZelacDE.Squamous cell carcinoma of the skin.Plast Reconstr Surg.2004; 114(6): 82e–94e.
16.
SchmultsCD, KariaPS, CarterJB, HanJ, QureshiAA.Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: a 10-year, single-institution cohort study.JAMA Dermatol.2013; 149(5): 541–547.
17.
ChrenMM, LinosE, TorresJS, StuartSE, ParvataneniR, BoscardinWJ.Tumor recurrence 5 years after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma.J Invest Dermatol.2013; 133(5): 1188–1196.
18.
BrantschKD, MeisnerC, SchonfischB.Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study.Lancet Oncol.2008; 9(8): 713–720.
19.
CherpelisBS, MarcusenC, LangPG.Prognostic factors for metastasis in squamous cell carcinoma of the skin.Dermatol Surg.2002; 28(3): 268–273.
20.
McCordMW, MendenhallWM, ParsonsJT.Skin cancer of the head and neck with clinical perineural invasion.Int J Radiat Oncol Biol Phys.2000; 47(1): 89–93.
21.
StaskoT, BrownMD, CarucciJA.Guidelines for the management of squamous cell carcinoma in organ transplant recipients.Dermatol Surg.2004; 30 (4, pt 2): 642–650.
22.
KaraaA, KhachemouneA.Keratoacanthoma: a tumor in search of a classification.Int J Dermatol.2007; 46(7): 671–678.
23.
SchwartzRA.Keratoacanthoma: a clinicopathologic enigma.Dermatol Surg.2004; 30 (2, pt 2): 326–333.
24.
EdgeS, ByrdD, ComptonC, FritzA, GreeneF, TrottiA.AJCC Cancer Staging Manual.7th ed.New York, NY: Springer;2010.
25.
ChrenMM, SahayAP, SandsLP.Variation in care for nonmelanoma skin cancer in a private practice and a veterans affairs clinic.Med Care.2004; 42(10): 1019–1026.
26.
BrewsterAM, LeeJJ, ClaymanGL.Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma.J Clin Oncol.2007; 25(15): 1974–1978.
27.
BallSB, DawberRP.Treatment of cutaneous Bowen's disease with particular emphasis on the problem of lower leg lesions.Australas J Dermatol.1998; 39(2): 63–68.
28.
HoltPJ.Cryotherapy for skin cancer: results over a 5-year period using liquid nitrogen spray cryosurgery.Br J Dermatol.1988; 119(2): 231–240.
29.
DupreeMT, KiteleyRA, WeismantleK, PanosR, JohnstonePA.Radiation therapy for Bowen's disease: lessons for lesions of the lower extremity.J Am Acad Dermatol.2001; 45(3): 401–404.
30.
CoxNH, DysonP.Wound healing on the lower leg after radiotherapy or cryotherapy of Bowen's disease and other malignant skin lesions.Br J Dermatol.1995; 133(1): 60–65.
31.
JohnsonTM, RoweDE, NelsonBR, SwansonNA.Squamous cell carcinoma of the skin (excluding lip and oral mucosa).J Am Acad Dermatol.1992; 26 (3, pt 2): 467–484.
32.
KwonS, DongZM, WuPC.Sentinel lymph node biopsy for high-risk cutaneous squamous cell carcinoma: clinical experience and review of literature.World J Surg Oncol.2011; 9: 80.
33.
RossAS, SchmultsCD.Sentinel lymph node biopsy in cutaneous squamous cell carcinoma: a systematic review of the English literature.Dermatol Surg.2006; 32(11): 1309–1321.
34.
VenessMJ.Treatment recommendations in patients diagnosed with high-risk cutaneous squamous cell carcinoma.Australas Radiol.2005; 49(5): 365–376.
35.
TanPY, EkE, SuS, GiorlandoF, DieuT.Incomplete excision of squamous cell carcinoma of the skin: a prospective observational study.Plast Reconstr Surg.2007; 120(4): 910–916.
36.
BrodlandDG, ZitelliJA.Surgical margins for excision of primary cutaneous squamous cell carcinoma.J Am Acad Dermatol.1992; 27 (2, pt 1): 241–248.
37.
JosephAK, MarkTL, MuellerC.The period prevalence and costs of treating nonmelanoma skin cancers in patients over 65 years of age covered by medicare.Dermatol Surg.2001; 27(11): 955–959.
CoxNH, EedyDJ, MortonCA; Therapy Guidelines and Audit Subcommittee, British Association of Dermatologists. Guidelines for management of Bowen's disease: 2006 update.Br J Dermatol.2007; 156(1): 11–21.
40.
Thestrup-PedersenK, RavnborgL, ReymannF.Morbus Bowen: a description of the disease in 617 patients.Acta Derm Venereol.1988; 68(3): 236–239.
41.
McCombeD, MacGillK, AinslieJ, BeresfordJ, MatthewsJ.Squamous cell carcinoma of the lip: a retrospective review of the Peter MacCallum Cancer Institute experience 1979-88.Aust N Z J Surg.2000; 70(5): 358–361.
42.
SchellAE, RussellMA, ParkSS.Suggested excisional margins for cutaneous malignant lesions based on Mohs micrographic surgery.JAMA Facial Plast Surg.2013; 15(5): 337–343.
43.
BakerNJ, WebbAA, MacphersonD.Surgical management of cutaneous squamous cell carcinoma of the head and neck.Br J Oral Maxillofac Surg.2001; 39(2): 87–90.
44.
Jambusaria-PahlajaniA, MillerCJ, QuonH, SmithN, KleinRQ, SchmultsCD.Surgical monotherapy versus surgery plus adjuvant radiotherapy in high-risk cutaneous squamous cell carcinoma: a systematic review of outcomes.Dermatol Surg.2009; 35(4): 574–585.
National Comprehensive Cancer Network.Clinical Practice Guidelines in Oncology, Basal Cell and Squamous Cell Skin Cancers: Version 2.2012.FortWashington, PA; 2012.
47.
HolmkvistKA, RoenigkRK.Squamous cell carcinoma of the lip treated with Mohs micrographic surgery: outcome at 5 years.J Am Acad Dermatol.1998; 38 (6, pt 1): 960–966.
48.
MohsFE, SnowSN.Microscopically controlled surgical treatment for squamous cell carcinoma of the lower lip.Surg Gynecol Obstet.1985; 160(1): 37–41.
49.
LeibovitchI, HuilgolSC, RichardsS, PaverR, SelvaD.Scalp tumors treated with Mohs micrographic surgery: clinical features and surgical outcome.Dermatol Surg.2006; 32(11): 1369–1374.
50.
LeibovitchI, HuilgolSC, SelvaD, HillD, RichardsS, PaverR.Cutaneous squamous cell carcinoma treated with Mohs micro-graphic surgery in Australia I: experience over 10 years.J Am Acad Dermatol.2005; 53(2): 253–260.
51.
MohsF, LarsonP, IriondoM.Micrographic surgery for the microscopically controlled excision of carcinoma of the external ear.J Am Acad Dermatol.1988; 19(4): 729–737.
52.
MohsFE, ZitelliJA.Microscopically controlled surgery in the treatment of carcinoma of the scalp.Arch Dermatol.1981; 117(12): 764–769.
53.
SilapuntS, PetersonSR, GoldbergLH.Squamous cell carcinoma of the auricle and Mohs micrographic surgery.Dermatol Surg.2005; 31 (11, pt 1): 1423–1427.
54.
NiparkoJK, SwansonNA, BakerSR, TelianSA, SullivanMJ, KeminkJL.Local control of auricular, periauricular, and external canal cutaneous malignancies with Mohs surgery.Laryngoscope.1990; 100 (10, pt 1): 1047–1051.
55.
Kimyai-AsadiA, GoldbergLH, PetersonSR, SilapintS, JihMH.The incidence of major complications from Mohs micrographic surgery performed in office-based and hospital-based settings.J Am Acad Dermatol.2005; 53(4): 628–634.
56.
AsgariMM, BertenthalD, SenS, SahayA, ChrenMM.Patient satisfaction after treatment of nonmelanoma skin cancer.Dermatol Surg.2009; 35(7): 1041–1049.
57.
EssersBA, DirksenCD, NiemanFH.Cost-effectiveness of Mohs micrographic surgery vs surgical excision for basal cell carcinoma of the face.Arch Dermatol.2006; 142(2): 187–194.
58.
DuffyKL, McKennaJK, HadleyML, Tristani-FirouziP.Nonmelanoma skin cancers of the ear: correlation between subanatomic location and post-Mohs micrographic surgery defect size.Dermatol Surg.2009; 35(1): 30–33.
59.
BellHK, RhodesLE.Bowen's disease: a retrospective review of clinical management.Clin Exp Dermatol.1999; 24(4): 338–339.
60.
HoneycuttWM, JansenGT.Treatment of squamous cell carcinoma of the skin.Arch Dermatol.1973; 108(5): 670–672.
61.
TromovitchTA.Skin cancer: treatment by curettage and desiccation.Calif Med.1965; 103: 107–108.
62.
ChrenMM, SahayAP, BertenthalDS, SenS, LandefeldCS.Quality-of-life outcomes of treatments for cutaneous basal cell carcinoma and squamous cell carcinoma.J Invest Dermatol.2007; 127(6): 1351–1357.
63.
GrahamGF, ClarkLC.Statistical analysis in cryosurgery of skin cancer.Clin Dermatol.1990; 8(1): 101–107.
64.
PeikertJM.Prospective trial of curettage and cryosurgery in the management of non-facial, superficial, and minimally invasive basal and squamous cell carcinoma.Int J Dermatol.2011; 50(9): 1135–1138.
65.
KuflikEG, GageAA.The five-year cure rate achieved by cryosurgery for skin cancer.J Am Acad Dermatol.1991; 24 (6, pt 1): 1002–1004.
66.
AhmedI, Berth-JonesJ, Charles-HolmesS, O'CallaghanCJ, IlchyshynA.Comparison of cryotherapy with curettage in the treatment of Bowen's disease: a prospective study.Br J Dermatol.2000; 143(4): 759–766.
67.
BabingtonS, VenessMJ, CakirB, GebskiVJ, MorganGJ.Squamous cell carcinoma of the lip: is there a role for adjuvant radiotherapy in improving local control following incomplete or inadequate excision?ANZ J Surg.2003; 73(8): 621–625.
68.
VenessMJ, OngC, CakirB, MorganG.Squamous cell carcinoma of the lip: patterns of relapse and outcome. Reporting the Westmead Hospital experience, 1980-1997.Australas Radiol.2001; 45(2): 195–199.
69.
MortonCA, McKennaKE, RhodesLE; British Association of Dermatologists Therapy Guidelines and Audit Subcommittee, British Photodermatology Group. Guidelines for topical photodynamic therapy: update.Br J Dermatol.2008; 159(6): 1245–1266.
70.
de HaasER, SterenborgHJ, NeumannHA, RobinsonDJ.Response of Bowen disease to ALA-PDT using a single and a 2-fold illumination scheme.Arch Dermatol.2007; 143(2): 264–265.
71.
SalimA, LemanJA, McCollJH, ChapmanR, MortonCA.Randomized comparison of photodynamic therapy with topical 5-fluorouracil in Bowen's disease.Br J Dermatol.2003; 148(3): 539–543.
72.
MortonCA, WhitehurstC, MoseleyH, McCollJH, MooreJV, MackieRM.Comparison of photodynamic therapy with cryotherapy in the treatment of Bowen's disease.Br J Dermatol.1996; 135(5): 766–771.
73.
MortonC, HornM, LemanJ.Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or fluorouracil for treatment of squamous cell carcinoma in situ: results of a multicenter randomized trial.Arch Dermatol.2006; 142(6): 729–735.
74.
Fink-PuchesR, SoyerHP, HoferA, KerlH, WolfP.Longterm follow-up and histological changes of superficial nonmelanoma skin cancers treated with topical delta-aminolevulinic acid photodynamic therapy.Arch Dermatol.1998; 134(7): 821–826.
75.
LoveWE, BernhardJD, BordeauxJS.Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review.Arch Dermatol.2009; 145(12): 1431–1438.
76.
PerisK, MicantonioT, FargnoliMC, LozziGP, ChimentiS.Imiquimod 5% cream in the treatment of Bowen's disease and invasive squamous cell carcinoma.J Am Acad Dermatol.2006; 55(2): 324–327.
77.
HenggeUR, SchallerJ.Successful treatment of invasive squamous cell carcinoma using topical imiquimod.Arch Dermatol.2004; 140(4): 404–406.
78.
TantikunN.Treatment of Bowen's disease of the digit with carbon dioxide laser.J Am Acad Dermatol.2000; 43(6): 1080–1083.
79.
GordonKB, GardenJM, RobinsonJK.Bowen's disease of the distal digit: outcome of treatment with carbon dioxide laser vaporization.Dermatol Surg.1996; 22(8): 723–728.
80.
KirbyJS, MillerCJ.Intralesional chemotherapy for nonmelanoma skin cancer: a practical review.J Am Acad Dermatol.2010; 63(4): 689–702.
81.
EdwardsL, BermanB, RapiniRP.Treatment of cutaneous squamous cell carcinomas by intralesional interferon alfa-2b therapy.Arch Dermatol.1992; 128(11): 1486–1489.
82.
KimKH, YavelRM, GrossVL, BrodyN.Intralesional interferon alpha-2b in the treatment of basal cell carcinoma and squamous cell carcinoma: revisited.Dermatol Surg.2004; 30(1): 116–120.
83.
WickramasingheL, HindsonTC, WacksH.Treatment of neo-plastic skin lesions with intralesional interferon.J Am Acad Dermatol.1989; 20(1): 71–74.
84.
DeContiRC.Chemotherapy of squamous cell carcinoma of the skin.Semin Oncol.2012; 39(2): 145–149.
85.
ShinDM, GlissonBS, KhuriFR.Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer.J Clin Oncol.2002; 20(2): 364–370.
86.
GuentherLC, BarberK, SearlesGE.Non-melanoma skin cancer in Canada chapter 1: introduction to the guidelines.J Cutan Med Surg.2015; 19: 205–215.
